JP2024522201A - 置換された１，２－ジアミノヘテロサイクリック化合物誘導体の製造およびその薬剤としての用途 - Google Patents

置換された１，２－ジアミノヘテロサイクリック化合物誘導体の製造およびその薬剤としての用途 Download PDF

Info

Publication number
JP2024522201A
JP2024522201A JP2023576071A JP2023576071A JP2024522201A JP 2024522201 A JP2024522201 A JP 2024522201A JP 2023576071 A JP2023576071 A JP 2023576071A JP 2023576071 A JP2023576071 A JP 2023576071A JP 2024522201 A JP2024522201 A JP 2024522201A
Authority
JP
Japan
Prior art keywords
alkyl
mmol
compound
optionally substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522201A5 (https=
Inventor
ギソン ベク
ジャヒョク グ
スンギュ チョェ
ヨンファン パク
サイモン ウォード
ダレン ルグラン
ライアン ウエスト
ペネローペ ターナー
サミュエル マーラマイ
トリスタン ルイヨン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avelos Therapeutics Inc
Original Assignee
Avelos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avelos Therapeutics Inc filed Critical Avelos Therapeutics Inc
Publication of JP2024522201A publication Critical patent/JP2024522201A/ja
Publication of JP2024522201A5 publication Critical patent/JP2024522201A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023576071A 2021-06-09 2022-06-09 置換された１，２－ジアミノヘテロサイクリック化合物誘導体の製造およびその薬剤としての用途 Pending JP2024522201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108249.0A GB202108249D0 (en) 2021-06-09 2021-06-09 Compounds
GB2108249.0 2021-06-09
PCT/KR2022/008105 WO2022260441A1 (en) 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents

Publications (2)

Publication Number Publication Date
JP2024522201A true JP2024522201A (ja) 2024-06-11
JP2024522201A5 JP2024522201A5 (https=) 2026-04-28

Family

ID=76838874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023576071A Pending JP2024522201A (ja) 2021-06-09 2022-06-09 置換された１，２－ジアミノヘテロサイクリック化合物誘導体の製造およびその薬剤としての用途

Country Status (10)

Country Link
US (1) US20240300936A1 (https=)
EP (1) EP4352049A4 (https=)
JP (1) JP2024522201A (https=)
KR (1) KR20240006692A (https=)
CN (1) CN117529476A (https=)
AU (1) AU2022291332A1 (https=)
CA (1) CA3216629A1 (https=)
GB (1) GB202108249D0 (https=)
MX (1) MX2023014784A (https=)
WO (1) WO2022260441A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250096877A (ko) * 2022-12-12 2025-06-27 아벨로스테라퓨틱스 주식회사 치환된 헤테로고리 화합물 유도체 및 그의 약학적 용도
WO2024137979A2 (en) * 2022-12-23 2024-06-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Foxm1 inhibitors and their use in treating cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508223A (ja) * 2008-11-10 2012-04-05 ユニバーシティ オブ バーゼル トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用
JP2012509335A (ja) * 2008-11-20 2012-04-19 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 化合物
JP2016504289A (ja) * 2012-11-27 2016-02-12 トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング がん治療用のピリミジン−２，４−ジアミン誘導体
JP2017516826A (ja) * 2014-06-04 2017-06-22 トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856151B2 (ja) * 2010-05-12 2016-02-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
US9481670B2 (en) * 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508223A (ja) * 2008-11-10 2012-04-05 ユニバーシティ オブ バーゼル トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用
JP2012509335A (ja) * 2008-11-20 2012-04-19 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 化合物
JP2016504289A (ja) * 2012-11-27 2016-02-12 トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング がん治療用のピリミジン−２，４−ジアミン誘導体
JP2017516826A (ja) * 2014-06-04 2017-06-22 トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"CAS登録番号2411592-23-7, 1252031-03-0", REGISTRY（STN）[ONLINE], JPN7026000130, 11 March 2020 (2020-03-11), ISSN: 0005775476 *
ANUJA KOTASTHANE ET AL.: "Applying conformational selection theory to improve crossdocking efficiency in 3‐phosphoinositide d", PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, vol. 82, no. 3, JPN6026001006, 17 October 2013 (2013-10-17), pages 436 - 451, ISSN: 0005775475 *
GIOVANNI CERVI ET AL.: "Discovery of 2-(Cyclohexylmethylamino)pyrimidines as a New Class of Reversible Valosine Containing P", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 24, JPN6026001008, 12 December 2014 (2014-12-12), pages 10443 - 10454, ISSN: 0005775473 *
JESUS R. MEDINA ET AL.: "Structure-Based Design of Potent and Selective 3-Phosphoinositide-Dependent Kinase-1 (PDK1) Inhibito", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 6, JPN6026001007, 22 February 2011 (2011-02-22), pages 1871 - 1895, ISSN: 0005775474 *

Also Published As

Publication number Publication date
EP4352049A4 (en) 2025-05-21
EP4352049A1 (en) 2024-04-17
CN117529476A (zh) 2024-02-06
WO2022260441A1 (en) 2022-12-15
KR20240006692A (ko) 2024-01-15
GB202108249D0 (en) 2021-07-21
CA3216629A1 (en) 2022-12-15
US20240300936A1 (en) 2024-09-12
AU2022291332A1 (en) 2023-12-21
MX2023014784A (es) 2024-03-25

Similar Documents

Publication Publication Date Title
AU2017311645B2 (en) Pyridopyrimdinone CDK2/4/6 inhibitors
CN112384510B (zh) Rip1抑制性化合物以及制备和使用其的方法
KR102824962B1 (ko) 헤테로시클릭 rip1 억제 화합물
CN115996929B (zh) 腺苷A2a受体的拮抗剂
IL274938B2 (en) New compounds and their pharmaceutical preparations for the treatment of diseases
JP2020519589A (ja) Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物
WO2025016899A1 (en) Spirocyclic compounds for the treatment of cancer
KR20150028999A (ko) 5-아자인다졸 화합물 및 이의 사용 방법
TW202019899A (zh) Tlr7/8拮抗劑及其用途
AU2016287335A1 (en) TBK/IKKepsilon inhibitor compounds and uses thereof
JP2021515767A (ja) Ｅｒｋ５阻害剤の同定及び使用
KR102719881B1 (ko) 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
TW202122382A (zh) 乙內醯脲衍生物
KR20150090044A (ko) 아자퀴나졸린 카복사미드 유도체
EP3782997A1 (en) Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases
AU2021300831A1 (en) RIP1k inhibitors
JP2024522201A (ja) 置換された１，２－ジアミノヘテロサイクリック化合物誘導体の製造およびその薬剤としての用途
WO2020116662A1 (ja) シクロアルカン−１，３−ジアミン誘導体
JP2025541224A (ja) 置換されたヘテロ環化合物誘導体およびその薬学的用途
EA036060B1 (ru) Пиридопиримидиноновые ингибиторы cdk2/4/6
TW202545531A (zh) 氮—喹唑啉化合物之使用方法
WO2022128850A1 (en) Novel isoquinoline derivatives and pharmaceutical copositions thereof for the treatment of diseases
EA049492B1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
EA042105B1 (ru) Производные 2-амино-пиримидина в качестве ингибиторов циклинзависимых киназ
EA051808B1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250417

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260420